D. Western Therapeutics Institute, Inc. (FRA:6DW)

Market Cap	29.72M -9.7%
Revenue (ttm)	2.11M -17.7%
Net Income	-3.43M
EPS	-0.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.5050
Previous Close	0.5050
Day's Range	0.5050 - 0.5050
52-Week Range	0.4020 - 0.8550
Beta	n/a
RSI	50.43
Earnings Date	Feb 13, 2026

About FRA:6DW

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. The company is also developing DW-5LBT, a lidocain...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 21
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6DW

Financial Performance

In 2025, FRA:6DW's revenue was 387.62 million, a decrease of -17.70% compared to the previous year's 471.00 million. Losses were -632.09 million, -51.00% less than in 2024.

Financial numbers in JPY